Exact Sciences Corporation (NASDAQ:EXAS) has a beta of 1.36. The stock’s Relative Strength Index (RSI) is 29.13, with weekly volatility at 6.51% and ATR at 5.91. The EXAS stock’s 52-week price range has touched low of $70.75 and a $159.54 high. Its shares traded higher over the last trading session, gaining 0.29% on 05/19/21. The shares fell to a low of $93.6424 before closing at $96.86. Intraday shares traded counted 1.64 million, which was -3.94% lower than its 30-day average trading volume of 1.58M. EXAS’s previous close was $96.58 while the outstanding shares total 171.31M.
Investors have identified the Diagnostics & Research company Exact Sciences Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $16.09 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Exact Sciences Corporation (EXAS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For EXAS, the company has in raw cash 1.1 billion on their books with 314.15 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 1.78 billion total, with 628.91 million as their total liabilities.
EXAS were able to record -115.15 million as free cash flow during the 08/04/2021 quarter of the year, this saw their quarterly net cash flow reduce by -387.49 million. In cash movements, the company had a total of -77.23 million as operating cash flow.
Potential earnings growth for Exact Sciences Corporation (EXAS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/04/2021 quarter of the year, Exact Sciences Corporation recorded a total of 402.08 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 13.49% coming in sequential stages and their sales for the 08/04/2021 quarter reducing by -15.98%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 109.99 million trying to sell their products during the last quarter, with the result yielding a gross income of 292.08 million. This allows shareholders to hold on to 171.31M with the recently reported earning now reading -0.18 cents per share. This is a figure that compared to analyst’s prediction for their 08/04/2021 (-0.18 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.41 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on EXAS sounds very interesting.
Is the stock of EXAS attractive?
In related news, President and CEO, Conroy Kevin T sold 19,240 shares of the company’s stock in a transaction that recorded on May 03. The sale was performed at an average price of 131.09, for a total value of 2,522,172. As the sale deal closes, the President and CEO, Conroy Kevin T now sold 22,755 shares of the company’s stock, valued at 3,010,487. Also, Chief Science Officer, LIDGARD GRAHAM PETER sold 43,241 shares of the company’s stock in a deal that was recorded on Mar 11. The shares were price at an average price of 130.00 per share, with a total market value of 5,621,330. Following this completion of acquisition, the Chief Science Officer, LIDGARD GRAHAM PETER now holds 11,735 shares of the company’s stock, valued at 1,423,808. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.60%.